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Breast cancer is one of the most commonly diagnosed female cancers and a leading cause of cancer-related death
in women. Multiple factors are responsible for breast cancer and heritable factors have received much attention.
DNA damage in breast cancer is induced by prolonged exposure to estrogens, such as 17β-estradiol, daily social/
psychological stressors, and environmental chemicals such as polycyclic aromatic hydrocarbons (PAHs) and
heterocyclic amines (HCAs). DNA damage induced by estrogen and stress is an important factor in the
pathogenesis and development of breast cancer and is now recognized as a critical provision for chemoprevention
of breast cancer. In this review, we summarize the relationships between estrogen- and stress-induced DNA
damage with regard to the pathogenesis and development of breast cancer. We also discuss recent investigations
into chemoprevention using dietary flavonoids such as quercetin and isoflavones.
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Breast cancer comprises 18% of all female cancers and is
one of the most common malignant diseases among
women [1]. The mortality (rate per 100,000 populations)
is reported to be 21.9 in Japan and 89.2 in the United
States [1]. The etiology of breast cancer is primarily
unknown, but an estimated one quarter of all breast
cancers may be caused by heritable factors [2]. These
include tumor suppressor genes that encode the DNA
repair enzyme breast cancer susceptibility gene 1/2
(BRCA1/2), and the transcription factor p53, which tar-
gets stress response genes [3, 4]. In addition, mutations
in the gene encoding the protein and lipid phosphatase
and tensin homologue (PTEN), are also detected in
sporadic breast cancer [5].
In addition to heritable factors, endogenous and exogen-
ous factors levels are also thought to be involved in breast
cancer. For example, prolonged exposure to estrogens,* Correspondence: shimoi@u-shizuoka-ken.ac.jp
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social/psychological stressors and environmental chemi-
cals such as polycyclic aromatic hydrocarbons (PAHs) and
heterocyclic amines (HCAs) increase the risk of breast
cancer [6, 7]. DNA damage by various inducers is a well-
known contributor to cancer, including breast cancer.
Interestingly, estrogens and their metabolites have been
shown to form DNA adducts, which damages DNA and
leads to breast cancer [8]. We previously reported that
oxidative DNA damage was induced in peripheral blood
cells of mice exposed to social isolation stress for 7 days
[9]. It was shown that stress hormones, such as
glucocorticoid and catecholamines, induced DNA damage
[10–12]. Interestingly, treatment with stress hormone
blockers was shown to reduce the risk of death from
breast cancer [13] And, an in vitro assay showed that
stress hormones are potent inducers of migratory activity
in breast cancer [14]. Common PAHs include benzo[a]-
pyrene (BaP) and benz[a]anthracen (BaA), and BaP is
widely distributed in smoked and grilled meat and fish,
and BaA is present in the atmosphere because of incom-
plete combustion of fossil fuels. These PAHs have beenle is distributed under the terms of the Creative Commons Attribution 4.0
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cing DNA damage, such as the formation of DNA
adducts, in various tissues [15–18]. Indeed, PAHs have
been widely used to experimentally induce breast carcino-
genesis [6]. HCAs are a group of mutagenic compounds
that are formed during a reaction between amino acids,
creatine/creatinine and sugar at high temperatures; there-
fore, they are found in well-cooked meats [19]. These
compounds include 2-amino-1-methyl-6-phenylimidazo
[4,5-b] pyridine (PhIP), which is a carcinogen that
increases the risk of breast cancer by inducing DNA
damage [20, 21]. The mechanism by which these in-
ducers evoke breast cancer remains unknown, but
DNA damage is commonly regarded as an important
contributor to breast cancer.
DNA damage occurs often and is usually repaired by
intracellular DNA repair mechanisms. If DNA repair
mechanisms fail, then cells are programmed to undergo
apoptosis. However, if apoptosis is prevented, somatic
mutations continue to accumulate, leading to cancer
initiation and progression [22, 23]. DNA damage has been
shown to trigger various cellular responses such as DNA
repair, activation of cell cycle checkpoints, and apoptosis.
Activation of checkpoints delays cell cycle progression to
facilitate DNA repair or eliminate damaged cells through
apoptosis. Defects in these processes contribute to the ini-
tiation of cancer, and people with inherited DNA repair
deficiency are predisposed to developing cancer [24, 25].
As shown in Fig. 1, PAHs, estrogens, estrogen metabo-
lites, physical/psychological stress induce DNA damage
in breast cancer, and the accumulation can lead to an
increase in breast cancer risk [26, 27]. For decades, re-
searchers have investigated estrogen-dependent breast
cancer and the underlying mechanisms have been eluci-
dated in detail. More recently, attention has focused on
how physical/psychological stresses induce DNA damageFig. 1 Various factors can cause DNA damage and increase the risk
of breast cancerand recent reports have shown that stress alters DNA
repair mechanisms [28, 29].
Stress-mediated DNA damage plays an important role
in the pathogenesis and development of breast cancer in
addition to estrogen-mediated DNA damage. Studying
the relationship between stress-mediated and estrogen-
mediated DNA damage in relation to breast cancer has
been recognized as a critical provision for the chemopre-
vention of breast cancer. In this review, we aim to consoli-
date the published findings regarding the relationships
between estrogen-mediated and stress-mediated DNA
damage in relation to the pathogenesis and development
of breast cancer. We also introduce recent findings about
the chemoprevention of breast cancer with dietary flavo-
noids such as quercetin and isoflavones.
Estrogen and breast cancer
Steroid hormones are important markers of breast can-
cer status [30, 31], particularly estrogens and their me-
tabolites, which increase the risk of breast cancer [32].
Estrogens are endogenous sex hormones and play
important roles in the development and maintenance of
reproductive organs and tissue differentiation [33]. High
estrogen levels in the breast are associated with an in-
creased cancer risk in women after menopause and
elevation of plasma estrogen levels was associated with
breast cancer development [30, 34–36]. We previously
described that the causes of estrogen-related breast
cancer can be divided into two factors [37]. One is the
induction of excess proliferation by estrogen receptor
(ER) signaling and disrupted DNA repair resulting in the
accumulation of DNA damage [38, 39]. The second is
DNA damage caused by estrogen-derived metabolites
modified by the cytochrome P450 (CYP) 1 family. Metab-
olism of estrogen is also a key factor in ER-independent
carcinogenic effects [40].
The most common estrogen in breast tissue is E2,
which is mainly produced by ovarian steroidogenesis in
premenopausal women. There are two pathways leading
to DNA damage by E2: (1) the release of estrogen-DNA
adducts from the DNA backbone leaving depurinated
sites prone to errors in DNA repair and mutations, and
(2) generation of reactive oxygen species (ROS), such as
superoxide anion, produced by redox-cycling of catechol
estrogens, which cause oxidative DNA damage [40]. The
metabolism pathways of estrogen are extremely com-
plex, and involve the production of many metabolites by
many enzymes (Fig. 2). Endogenous E2 is hydroxylated
to catechol estrogens 2-OHE2 and 4-OHE2 by CYP1A1
and CYP1B1, respectively [41, 42]. Catechol estrogens
are then methylated by catechol-O-methyltransferase
(COMT) to 2-methoxy-E2 and 4-methoxy-E2, respect-
ively. 2-methoxy-E2 can inhibit angiogenesis and sup-
presses tumor growth [43]. One active metabolite is E2-
Fig. 2 Schematic representation of typical estrogen metabolism. 17β-Estradiol (E2) is most common estrogen in the breast tissue. Endogenous E2
is hydroxylated to two types of catechol estrogens, 2-hydroxy-E2 (2-OHE2) and 4-hydroxy-E2 (4-OHE2), by Cytochrome P450 (CYP) 1A1 and CYP1B1,
respectively. These catechol estrogens are further methylated to individual methoxide E2, 2-methoxy-E2 (2-MeOE2) and 4-methoxy-E2 (4-MeOE2), by
catechol-O-methyltransferase (COMT). Methoxide E2 are basically ineffective compounds to DAN damage, and 2-MeOE2 exerts suppressive effects for
tumor growth. On the other hand, 4-OHE2 is oxidized by any oxidative enzyme and/or metal ion, and formed E2-3,4-quinone (E2-3,4-Q), which can
react with DNA directly
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tion of 4-OHE2 by any oxidative enzyme or metal ion
[44, 45]. E2-3,4-Q can react with DNA directly and bind
covalently to guanine and/or adenine, destabilizing the
glycosylated bond [46–48]. In vitro and in vivo investiga-




adenine adducts, can be depurinated at the glycoside
bond, creating potentially mutagenic abasic sites
[35, 49–51]. Wen et al. reported that the accumulation
of catechol estrogens in breast tissue in response to in-
creased CYP1B1 and reduced COMT expression can
increase breast cancer risk [52]. We previously reported
that 4-OHE2 and COMT inhibitors can induce phos-
phorylated histone H2AX, a marker of DNA damage, in
human MCF-7 breast cancer cells [27]. These findings
support the significant role of estrogen metabolites in
breast cancer development.
The reduction of estrogen quinones to hydroqui-
nones and catechols can produce ROS, such as 8-oxo-
7, 8-dihydro-2′-deoxyguanosine (8-oxo-dG), that cause
oxidative DNA damage [53, 54]. Frequent errors in
DNA repair can lead to the accumulation of point mu-
tations over a long period of time. Once these muta-
tions cause sufficient DNA damage, the risk of breast
cancer is elevated [55].Stress and breast cancer
Stress is a state of threatened homeostasis provoked by
various stressors. Physiological systems adapt to stress in
various ways, including activation of the hypothalamus-
pituitary-adrenal axis (HPA) as well as the sympathetic-
adrenal-medullary (SAM) system, which stimulates the
production of stress hormones. Prolonged or repeated
activation of the HPA and SAM can interfere with their
control of other physiological systems, increasing the
risk of physical and psychiatric disorders [56, 57]. For
several decades, studies have shown that psychological/
physiological stress can contribute to the development
and progression of breast cancer [12, 58–61], although
the precise mechanisms have not been fully elucidated.
Case studies have shown an increased risk of breast
cancer among women with a previous adverse life event
or multiple stressful life changes [62–66]. Lillberg et al.
investigated the relationship between stressful life events
(such as divorce or separation, death of a loved one, loss
of a job, increase in amount of work, interpersonal con-
flict, financial problems) and risk of breast cancer among
10,808 women from a Finnish Twin Cohort. They sug-
gested a role for stressful life events in breast cancer
etiology, and one of this mechanisms is associated with
various hormonal secretion [67]. Animal experiments
have also demonstrated the promotion of breast cancer
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suggested that stress caused by social isolation increased
the growth and malignancy of breast cancer tumors in
rodents [68, 69]. Chronic restraint stress has also been
shown to increase the rate of primary tumor growth and
cause primary tumor to become more metastatic in
mouse models of breast cancer [70, 71].
Disturbed circadian rhythm caused by working night
shifts has been implicated as a potential risk factor for
endocrine-related cancers such as breast cancer [72–74].
Figueiro et al. reported that exposure to light during the
night increased cortisol levels in humans [75]. In addition,
the international Agency for Research on Cancer has
concluded that shift-work is potentially carcinogenic to
humans [76].
One possible contributor to stress-induced cancer is
the production of stress hormones, such as glucocorti-
coids (cortisol for humans, corticosterone for rodents)
and catecholamines (adrenaline and noradrenaline),
which cause damage to DNA [77, 78]. Exposure to
physiological/psychological stress induces the produc-
tion of stress hormones, which bind directly to the cell
surface via their specific receptors. Receptor activation
induces various cellular responses [79]. Okamoto et al.
and Djelic et al. reported that noradrenaline induces
DNA breaks and produces ROS [80, 81]. Studies in
humans and animals have demonstrated that exposure
to stress can contribute to DNA damage [78, 82]. We
also demonstrated that stress caused by social isolation
induced oxidative DNA damage in mouse peripheral
blood cells using a comet assay with formamidopyrimi-
dine DNA glycosylase (FPG). FPG has N-glucosidase
and AP-lyase activities that are specific for oxidative
DNA damage [9]. Flint et al. suggested that cortisol and
catecholamines induce DNA damage and interfere with
DNA repair, contributing to the transformation of mur-
ine 3T3 cells [77]. Hara et al. confirmed that chronic
stress causes DNA damage via catecholamine produc-
tion using animal models and cell lines [11, 83]. They
suggested that activation of the β2-adrenaline receptor
stimulates β-arrestin-1, activating Akt/Mdm2. Mdm2 is
an E3-ubiquitin ligase and promotes the degradation of
p53. Stimulation of this signaling pathway can cause DNA
damage in the frontal cortex of the brain. These results
provide evidence that exposure to chronic stress and
continuous activation of the sympathetic nervous system
can influence genomic integrity in various tissues.
We have previously reported that noradrenaline/adren-
aline receptors can induce the activation of several signal-
ing pathways in breast cancer cells to promote invasion
[84]. It remains unclear whether this pathway is stimu-
lated by DNA damage caused by catecholamine in our
report. However, we have shown that DNA damage is
induced by noradrenaline/adrenaline receptors in non-tumorigenic human breast cells [85], suggesting that stress
and stress hormones play important roles in the initi-
ation and development of breast cancer via DNA dam-
age. Many studies have demonstrated that stress leads
to stress hormone production, which increases the risk
of breast cancer by DNA damage. However, further
research is required to clarify the mechanisms under-
lying stress-induced breast cancer.
Estrogen, stress, DNA damage, and cancer
The initiation and development of breast cancer can be
promoted by DNA damage caused by estrogen metabo-
lites and stress. We previously reported the synergistic
effects of estrogen metabolites and stress hormones on
DNA damage [85]. Combined exposure to 4-OHE2 and
noradrenaline at the concentration where 4-OHE2 or
noradrenaline alone did not cause DNA damage in-
creased DNA damage, including the formation of AP
sites and γ-H2AX in human mammary MCF-10A cells
[86, 87]. Based on these findings, we suggest that co-
exposure to estrogen metabolites and stress represents a
novel risk factor in our daily life.
Chemoprevention with dietary flavonoid
Diets that are rich in fruit and vegetables have been
proven to decrease cancer risk [88, 89]. In addition to
beneficial nutrients such as vitamins and minerals, phy-
tochemicals such as flavonoids and other phenolic com-
pounds contribute to these protective effects. Flavonoids
are the most common polyphenolic compounds found
in plants. We have previously summarized the protective
effects of flavonoids against breast cancer; many flavo-
noids can ameliorate breast cancer by regulating the
activity of CYP1 enzymes in animals and humans [37].
Endogenous E2 is hydroxylated to catechol estrogens by
CYP1 enzymes; CYP1A1 and CYP1A2 convert E2 to non
carcinogenic 2-OHE2, and CYP1B1 converts E2 to car-
cinogenic 4-OHE2 [41, 42]. Using ethoxyresorufin-O-
deethylase, we have shown the effects of 18 flavonoids
on CYP1 activity [90] and have summarized these find-
ings in a previous review [37]. The double bond between
the C2- and C3-positions of the C-ring means that fla-
vones and flavonols have a tendency to selectively inhibit
CYP1B1 activity rather than flavanones. The methoxy
substituent on the B-ring also contributes to the strong
inhibitory effects on CYP1 activity; acacetin, diosmetin,
chrysoeriol, isorhamnetin, tamarixetin, and kaempferide
all have strong inhibitory effects on CYP1B1 activity.
The regulation of DNA damage is critical for the che-
moprevention of estrogen- and stress-dependent breast
cancer. Quercetin, including aglycone and its glycosides,
is one of the most well researched dietary flavonoids,
and abundant in onions. Their beneficial effects on the
prevention of various diseases and bioavailability have
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representation of typical quercetin metabolism in Fig. 3.
We have investigated the effects of quercetin and its prin-
cipal metabolite quercetin-3-O-glucuronide, on breast can-
cer and found that these flavonoids can decrease 4-OHE2-
and noradrenaline-induced DNA damage by preventing
the binding of noradrenaline to the adrenaline receptor
[85]. Conversely, a high-dose of quercetin is known to in-
duce oxidative DNA damage [96, 97]. Yamashita et al.
found that 10–100 μM of quercetin induced DNA damage
[96] and Murota et al. reported that the major circulating
forms of quercetin in human plasma (quercetin sulfate
and glucuronide) are present at concentrations of 0.1–
1 μM [98]. The average dietary intake of quercetin is
16 mg/day, which is a safe concentration regarding DNA
damage and could prevent various diseases [96]. We
have also shown that noradrenaline induces ROS pro-
duction, MAPKs activation, pro-tumorigenic gene ex-
pression, and invasion in breast cancer MDA-MB-231
cells, but not in non-tumorigenic MCF-10A cells. In
addition, 0.1 μM of the quercetin metabolite quercetin-Fig. 3 Schematic representation of typical quercetin metabolism. Quercetin
as glycosides such as quercetin-3-O-glucoside (isoquercitrin), −3-O-rutinoside
deglycosylated into their aglycone form (quercetin) by mucosal and bacterial
metabolized to glucuronidated and/or sulfated derivatives (ex. Quercetin-3-O-
diphospho-glucuronosyltransferase (UGT), respectively. Additionally, quercetin
and isorhamnetin by catechol-O-methyl transferase (COMT), and further glucr
more appropriate metabolites for quercetin aglycone for evaluation of the be
glycosides and aglycone form3-O-glucuronide suppresses these responses by influen-
cing the adrenaline receptor [84]. Following onion
consumption, 1 μM of quercetin-3-O-glucuronide is
detected in human plasma (500 g, two onions, contain-
ing quercetin glycosides equivalent to 150 mg quercetin
aglycone) [98], and to our knowledge, we were the first
to demonstrate the inhibitory action of quercetin-3-O-
glucuronide at concentrations detectable in human
plasma after onion consumption. Noradrenaline stimu-
lates proliferation and promotes migration of MDA-
MB-231 human breast cancer cells by activating many
signaling pathways [84, 99]. Stress hormone-induced DNA
damage may contribute to cancer risk. Thus, blocking
interaction of noradrenaline with its receptor using quer-
cetin metabolites may suppress various cancer-causing
pathways. Taken together, these findings suggest that diet-
ary intake of quercetin may be a powerful chemopreventive
factor for estrogen- and/or stress-related breast cancer.
Phytoestrogens are compounds of plant origin with
estrogen-like activity. They act as weak agonists, antag-
onists, or modulators of human ERs. Isoflavones areis one of the major flavonoids, and present in plant foods, principally
(rutin) and -4′-O-glucoside. When consumed, quercetin glycosides are
enzymes in the alimentary canal. Subsequently, quercetin aglycone is
glucronide and -3′-O-sulphate) by sulfotransferase (SULT) and uridine 5′-
aglycone is also methylated to methoxide quercetin such as tamarixetin
onidated. Hece, the glucuronidated and/or sulfated derivatives may be
neficial effects of quercetin under physiological conditions than their
Fig. 4 Summary of DNA damage-induced breast cancer by estrogen and stressors. Stressors induced stress hormones such as catecholamines
and glucocorticoids, and these.stress hormones are recognized by each receptor, adrenaline receptor (AR) and glucocorticoid receptor (GR). These
receptors activate the downstream pathways. AR stimulate the Gs/protein kinase A (PKA) pathway and phosphoinositide 3-kinase (PI3K)/Akt-mediated
murine double minute 2 (MDM2), leading to p53 ubiquitination and degradation [11]. GR regulates the expression of factors critical for DNA damage
signaling; Chek1 (Chk1), Chk2, cell division cycle 25 (Cdc25), and Rad9 [77]. Estrogen metabolites and noradrenaline induced DNA damage with Ataxia
telangiectasia mutated (ATM) activation [27, 85]. The activation of these pathways leads to DNA damage, and accumulation of DNA damages result in
induction of breast cancer
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vones such as genistein and daidzein, and the metabolite
equol can bind to ERs [100] and have chemopreventive or
the opposite effects on breast cancer [37, 101]. In addition,
genistein modulates CYP1 expression and DNA damage
in breast cells. Wei et al. suggested that physiological con-
centrations of genistein (5 μM) induce ROS production
and stimulate breast cancer cell proliferation by indu-
cing CYP1B1 expression [102]. However, Leung et al.
reported that oxidative DNA damage caused by PAH
was inhibited by genistein (5 μM) in human breast cells
by suppressing CYP1 [103]. These findings showed that
genistein can both increase and decrease the risk of
breast cancer. Taken together, the roles of isoflavones
in breast cancer remain unclear and further research is
required to elucidate them.
Conclusion
Studies have identified various risk factors for breast can-
cer, and many have supported the hypothesis that estrogen
metabolites and stress are key risk factors for breast cancer.
Although the mechanisms through which estrogens and
stress contribute to breast cancer are complex, DNA dam-
age is possibly involved. As summarized in Fig. 4, a part of
these signaling pathways were investigated so far. Estrogen
metabolite and stress hormone activates Ataxia telangiecta-
sia mutated (ATM) [27, 85], and stress hormones are rec-
ognized by each receptor, followed by activation of thedownstream pathways [11, 77], resulting in induction of
DNA damage. Elucidating the underlying mechanisms in
more detail will be of crucial importance for the develop-
ment of therapeutic or preventative strategies targeting
breast cancer.
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